MEASURE 1 | ENRADAS | |||||
---|---|---|---|---|---|---|
Characteristic | Primary Analysis Set (N = 168)a | Sensitivity Analysis Set 1 (N = 175)b | Sensitivity Analysis Set 2 (N = 201) | Primary Analysis Set (N = 69)a | Sensitivity Analysis Set 1 (N = 78)b | Sensitivity Analysis Set 2 (N = 122) |
mSASSS | 9.6 ± 14.1 | 9.0 ± 14.05 | 6.4 ± 10.4 | 9.9 ± 13.8 | 9.8 ± 13.3 | 7.9 ± 10.5 |
CRP (mg/L) | 18.3 ± 23.4 | 18.1 ± 22.1 | 17.5 ± 21.1 | 8.8 ± 9.7 | 10.1 ± 11.5 | 10.1 ± 12.0 |
Smoker, n (%) | 42 (25.0) | 33 (18.9) | 45 (22.4) | 31 (44.9) | 35 (44.9) | 56 (46.3) |
Time since diagnosis, years | 7.2 ± 8.0 | 6.3 ± 7.0 | 6.9 ± 7.7 | 10.3 ± 11.1 | 8.9 ± 10.5 | 8.6 ± 10.1 |
NSAID use, n (%) | 166 (98.8) | 174 (99.4) | 199 (99.0) | 69 (100) | 78 (100) | 122 (100) |
Corticosteroid use, n (%) | 23 (13.7) | 23 (13.1) | 26 (12.9) | Not available | Not available | 78 (63.9)c |
Age in years | 41.0 ± 12.6 | 40.3 ± 12.8 | 41.3 ± 12.6 | 42.6 ± 10.8 | 42.0 ± 10.4 | 42.8 ± 10.2 |
Male, n (%) | 123 (73.2) | 122 (69.7) | 141 (70.1) | 46 (66.7) | 56 (71.8) | 84 (68.9) |
HLA-B27 positive, n (%) | 136 (82.9) | 139 (81.8) | 155 (79.5) | 61 (88.4) | 72 (92.3) | 110 (90.2) |